Crossmark

Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition

Crossref DOI link: https://doi.org/10.1038/s41388-018-0268-2

Published Online: 2018-05-10

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weeden, Clare E.

Ah-Cann, Casey

Holik, Aliaksei Z.

Pasquet, Julie

Garnier, Jean-Marc

Merino, Delphine

Lessene, Guillaume

Asselin-Labat, Marie-Liesse https://orcid.org/0000-0001-7082-6076
License Information

Text and Data Mining valid from 2018-05-10
More Information

Article History

Received: 30 October 2017

Revised: 19 March 2018

Accepted: 29 March 2018

First Online: 10 May 2018

Compliance with ethical standards

:

: CEW, CAC, AZH, JP, JMG, GL and MLAL are employees of the Walter and Eliza Hall Institute of Medical Research that receives research funding and milestone payments in relation to venetoclax (ABT199). The laboratory of GL and M-LA-L received research funding from Servier. The remaining authors declare no conflict of interest.